Articles from August 2012
Posted by Site Administrator on August 17, 2012
Researchers have discovered that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease. This finding could lead to a new treatment for the debilitating neurological disease, which affects approximately 30,000 Americans.
Categories: Research News, Treatments
| 
Tags: ALS, ALS community, ALS research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Brigham and Women’s Hospital, Harvard Medical School, Howard Weiner, Howard Weiner Robert L Kroc Professor of Neurology, Lou Gehrig's disease, Massachusetts General Hospital, Massachusetts General Hospital ALS Multidisciplinary Clinic, Merit Cudkowicz, monocytes biomarker ALS, Oleg Butovsky, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, Robert L. Kroc Professor of Neurology, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, The Journal of Clinical Investigation
| 
No comments
Posted by Site Administrator on August 16, 2012
“This study shows that cytoskeletal defects can lead to ALS, and tell us that we should be looking closer at these pathways in the development of disease.”
Categories: Research News
| Tags: ALS, ALS community, ALS cytoskeleton, ALS research, amyotrophic lateral sclerosis, Bob Brown, Bob Stehlin, C9ORF72, cytoskeletal defects ALS, familial ALS, FUS, Gene Mutation ALS, inherited ALS, John Landers, Jonathan Glass, profilin 1 gene, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, SOD1, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, TDP43, University of Massachusetts Medical School
| No comments
Posted by Site Administrator on August 15, 2012
Researchers in Japan have pinpointed a protein which could slow the development of amyotrophic lateral sclerosis (ALS), a degenerative disease of the nerve cells that gradually causes muscle weakness and atrophy.
Categories: Research News, Treatments
| Tags: ALS, ALS community, ALS diagnosis, ALS diagnostics, ALS research, ALS slow onset, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, breakthrough, Gifu Pharmaceutical University, Hideaki Hara, Hideki Nishitoh, Lou Gehrig's disease, motor nerve cells, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, superoxide dismutase (SOD1) enzyme, transmembrane glycoprotein NMB (GPNMB), University of Miyazaki
| No comments
Posted by Site Administrator on August 13, 2012
Chaim Lebovits, CEO and president of BrainStorm Cell Therapeutics in Israel, discusses the potential for the company’s developmental therapy and its implications for patients with ALS. He is joined in this segment by Rasheda Ali, daughter of Muhammad Ali, and an advisory board member for BrainStorm.
Categories: Research News, Technology, Treatments
| Tags: ALS, ALS community, ALS research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, BrainStorm Cell Therapeutics, Chaim Lebovits, Hadassah Medical Center, Lou Gehrig's disease, Massachusetts General Hospital, Muhammad Ali, NurOwn, RASCALS Foundation, Rasheda Ali, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis
| No comments
Posted by Site Administrator on August 13, 2012
“We are moved by the remarkable results observed following treatment with NurOwn,” said Professor Avi Israeli, BrainStorm’s Chairman of the Board. “We are hopeful that we will continue to see this kind of improvement in all the patients participating in our current and future clinical trials.”
Categories: Research News, Technology, Treatments
| Tags: ALS, ALS community, ALS orphan drug designation status, ALS research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, BrainStorm Cell Therapeutics, compassionate use ALS, Hadassah Medical Center, Lou Gehrig's disease, Massachusetts General Hospital, NurOwn, Phase 1 and II clinical trial, Professor Avi Israeli, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, University of Massachusetts Medical School
| No comments
